Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | SCD | O00767 | 5/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943572 | 1.00 | RXFP1 (0.60) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 | |
| Hydrochloric Acid SCHEMBL25425 | 0.98 | RXFP1 (0.59) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 | |
| Trifluoroacetic Acid SCHEMBL27703342 | 0.94 | CYP2C9 (0.56) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 | |
| Tert-Butyl Formate SCHEMBL27728669 | 0.88 | RXFP1 (0.49) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL3528330 | 0.87 | P2RX7 (0.55) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL6917875 | 0.87 | RXFP1 (0.52) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 | |
| Hydrochloric Acid SCHEMBL3529996 | 0.85 | P2RX7 (0.54) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL10304326 | 0.84 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14SCD | |
| SCHEMBL8253848 | 0.83 | RXFP1 (0.77) | RXFP1SIGMAR1 | |
| SCHEMBL938133 | 0.83 | SLC6A2 (0.45) | RXFP1CYP2C9CYP2C19HTR2BMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302465-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | claimed |
| EP-2099755-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2009-09-16 | — | — | EP | claimed |
| EP-2091951-A2 | PYRIDO[2,3-B]PYRAZINE AND[1,8]-NAPHTYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2009-08-26 | — | — | EP | claimed |
| WO-2008062276-A2 | ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2007130468-A2 | PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-12-29 | — | — | US | disclosed |
| US-11325892-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3177292-B1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20190345123-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-11-14 | — | — | US | disclosed |
| US-10301273-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-08-10 | — | — | US | disclosed |
| US-5883098-A | USED AS TACHYKININ ANTAGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES, OPHTHALMIC DISEASES AND INFLAMMATORY DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
| US-5693804-A | USEFUL IN TREATING NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS AND ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0792269-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5658909-A | INHIBITION OF ABNORMALLY PHOSPHORYLATED PAIRED HELICAL FILAMENT EPITOPE FORMATION | MOLECULAR GERIATRICS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996015792-A9 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | — | 1996-09-12 | — | — | WO | disclosed |
| WO-1996016052-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015792-A1 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325892-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | RXFP1 434/4885CYP2C9 1952/4885CYP2C19 2808/4885 |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | RXFP1 434/4885CYP2C9 1952/4885CYP2C19 2808/4885 |
| US-10301273-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | RXFP1 434/4885CYP2C9 1952/4885CYP2C19 2808/4885 |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | RXFP1 434/4885CYP2C9 1952/4885CYP2C19 2808/4885 |
| US-20190345123-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | RXFP1 434/4885CYP2C9 1952/4885CYP2C19 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.